REMEGEN (09995.HK) saw its stock price soar 8.36% in intraday trading on Thursday, as investors reacted positively to the company's announcement regarding its significant presence at the upcoming European Society for Medical Oncology (ESMO) 2025 annual meeting.

The biopharmaceutical company revealed that it has secured the inclusion of 11 original research results at the prestigious conference, scheduled to take place in Berlin, Germany from October 17-21. Notably, REMEGEN's RC48-C016 Phase III clinical study of disitamab vedotin combination therapy for first-line urothelial carcinoma has been selected for the coveted "Late-Breaking Abstracts (LBA)" category, underscoring the study's academic importance and potential impact on cancer treatment.

In addition to the late-breaking presentation, REMEGEN will showcase 10 other studies at ESMO 2025, including two short oral presentations and eight poster presentations. These studies span multiple tumor types and treatment strategies, covering areas such as urothelial carcinoma, gastric cancer, and gynecological tumors. This comprehensive showcase is seen as a strong indication of REMEGEN's leading position in Antibody-Drug Conjugate (ADC) therapies and combination treatments, likely contributing to the positive market sentiment and the subsequent stock price surge.